TY - CHAP AU - Amaya-Amaya, J. PY - 2013 DA - 2013// TI - Rheumatoid arthritis BT - Autoimmunity: from bench to bedside PB - El Rosario University Press CY - Bogota ID - Amaya-Amaya2013 ER - TY - JOUR AU - Schett, G. AU - Gravallese, E. PY - 2012 DA - 2012// TI - Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment JO - Nat Rev Rheumatol VL - 8 UR - https://doi.org/10.1038/nrrheum.2012.153 DO - 10.1038/nrrheum.2012.153 ID - Schett2012 ER - TY - JOUR AU - Scott, D. L. AU - Wolfe, F. AU - Huizinga, T. W. PY - 2010 DA - 2010// TI - Rheumatoid arthritis JO - Lancet VL - 376 UR - https://doi.org/10.1016/S0140-6736(10)60826-4 DO - 10.1016/S0140-6736(10)60826-4 ID - Scott2010 ER - TY - JOUR AU - Haraoui, B. PY - 2011 DA - 2011// TI - Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire JO - Ann Rheum Dis VL - 70 UR - https://doi.org/10.1136/ard.2011.154179 DO - 10.1136/ard.2011.154179 ID - Haraoui2011 ER - TY - JOUR AU - Kameda, H. PY - 2010 DA - 2010// TI - Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial JO - Mod Rheumatol VL - 20 UR - https://doi.org/10.3109/s10165-010-0324-4 DO - 10.3109/s10165-010-0324-4 ID - Kameda2010 ER - TY - JOUR AU - Kaneko, Y. PY - 2016 DA - 2016// TI - Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study) JO - Ann Rheum Dis VL - 75 UR - https://doi.org/10.1136/annrheumdis-2015-208426 DO - 10.1136/annrheumdis-2015-208426 ID - Kaneko2016 ER - TY - STD TI - Genovese MC, et al. VX-509 (decernotinib), an oral selective Janus kinase 3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol. 2015. https://doi.org/10.1002/art.39473 [Epub ahead of print]. ID - ref7 ER - TY - JOUR AU - Singh, J. A. PY - 2016 DA - 2016// TI - 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis JO - Arthritis Rheumatol VL - 68 UR - https://doi.org/10.1002/art.39480 DO - 10.1002/art.39480 ID - Singh2016 ER - TY - JOUR AU - Kaneko, Y. AU - Takeuchi, T. PY - 2017 DA - 2017// TI - Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis JO - Int Immunol VL - 29 UR - https://doi.org/10.1093/intimm/dxx055 DO - 10.1093/intimm/dxx055 ID - Kaneko2017 ER - TY - JOUR AU - Takeuchi, T. PY - 2017 DA - 2017// TI - Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease JO - Proc Japan Acad Series B VL - 93 UR - https://doi.org/10.2183/pjab.93.038 DO - 10.2183/pjab.93.038 ID - Takeuchi2017 ER - TY - JOUR AU - Saeki, Y. PY - 2012 DA - 2012// TI - Current treatments of rheumatoid arthritis: from the ‘NinJa’ registry JO - Expert Rev Clin Immunol VL - 8 UR - https://doi.org/10.1586/eci.12.35 DO - 10.1586/eci.12.35 ID - Saeki2012 ER - TY - JOUR AU - Kaneko, Y. AU - Kondo, H. AU - Takeuchi, T. PY - 2013 DA - 2013// TI - American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints JO - J Rheumatol VL - 40 UR - https://doi.org/10.3899/jrheum.130166 DO - 10.3899/jrheum.130166 ID - Kaneko2013 ER - TY - STD TI - SIMPONI ARIA (golimumab) [package insert]. Horsham: Janssen Biotech, Inc; 2017. ID - ref13 ER - TY - STD TI - XELJANZ (tofacitinib) [package insert]. Pfizer Inc: New York; 2018. ID - ref14 ER - TY - STD TI - RINVOQ (upadacitinib) [package insert]. Chicago: AbbVie Inc; 2019. ID - ref15 ER - TY - STD TI - ACTEMRA (tocilizumab) [package insert]. South San Francisco: Genentech, Inc; 2019. ID - ref16 ER - TY - JOUR AU - Tasaki, S. PY - 2018 DA - 2018// TI - Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-05044-4 DO - 10.1038/s41467-018-05044-4 ID - Tasaki2018 ER - TY - JOUR AU - Mor, A. AU - Abramson, S. B. AU - Pillinger, M. H. PY - 2005 DA - 2005// TI - The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction JO - Clin Immunol VL - 115 UR - https://doi.org/10.1016/j.clim.2004.12.009 DO - 10.1016/j.clim.2004.12.009 ID - Mor2005 ER - TY - JOUR AU - Neumann, E. PY - 2010 DA - 2010// TI - Rheumatoid arthritis progression mediated by activated synovial fibroblasts JO - Trends Mol Med VL - 16 UR - https://doi.org/10.1016/j.molmed.2010.07.004 DO - 10.1016/j.molmed.2010.07.004 ID - Neumann2010 ER - TY - JOUR AU - Noss, E. H. AU - Brenner, M. B. PY - 2008 DA - 2008// TI - The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis JO - Immunol Rev VL - 223 UR - https://doi.org/10.1111/j.1600-065X.2008.00648.x DO - 10.1111/j.1600-065X.2008.00648.x ID - Noss2008 ER - TY - JOUR AU - Koch, A. E. PY - 1994 DA - 1994// TI - Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis JO - J Clin Invest VL - 94 UR - https://doi.org/10.1172/JCI117414 DO - 10.1172/JCI117414 ID - Koch1994 ER - TY - JOUR AU - Leech, M. T. AU - Morand, E. F. PY - 2013 DA - 2013// TI - Fibroblasts and synovial immunity JO - Curr Opin Pharmacol VL - 13 UR - https://doi.org/10.1016/j.coph.2013.04.001 DO - 10.1016/j.coph.2013.04.001 ID - Leech2013 ER - TY - JOUR AU - Croft, A. P. PY - 2019 DA - 2019// TI - Distinct fibroblast subsets drive inflammation and damage in arthritis JO - Nature VL - 570 UR - https://doi.org/10.1038/s41586-019-1263-7 DO - 10.1038/s41586-019-1263-7 ID - Croft2019 ER - TY - JOUR AU - Wynn, T. A. PY - 2019 DA - 2019// TI - Two types of fibroblast drive arthritis JO - Nature VL - 570 UR - https://doi.org/10.1038/d41586-019-01594-9 DO - 10.1038/d41586-019-01594-9 ID - Wynn2019 ER - TY - JOUR AU - Zhang, F. PY - 2019 DA - 2019// TI - Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry JO - Nat Immunol VL - 20 UR - https://doi.org/10.1038/s41590-019-0378-1 DO - 10.1038/s41590-019-0378-1 ID - Zhang2019 ER - TY - JOUR AU - Miranti, C. K. AU - Brugge, J. S. PY - 2002 DA - 2002// TI - Sensing the environment: a historical perspective on integrin signal transduction JO - Nat Cell Biol VL - 4 UR - https://doi.org/10.1038/ncb0402-e83 DO - 10.1038/ncb0402-e83 ID - Miranti2002 ER - TY - JOUR AU - Yokosaki, Y. PY - 1994 DA - 1994// TI - The integrin alpha 9 beta 1 mediates cell attachment to a non-RGD site in the third fibronectin type III repeat of tenascin JO - J Biol Chem VL - 269 ID - Yokosaki1994 ER - TY - JOUR AU - Smith, L. L. PY - 1996 DA - 1996// TI - Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin JO - J Biol Chem VL - 271 UR - https://doi.org/10.1074/jbc.271.45.28485 DO - 10.1074/jbc.271.45.28485 ID - Smith1996 ER - TY - JOUR AU - Taooka, Y. PY - 1999 DA - 1999// TI - The integrin alpha9beta1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-1 JO - J Cell Biol VL - 145 UR - https://doi.org/10.1083/jcb.145.2.413 DO - 10.1083/jcb.145.2.413 ID - Taooka1999 ER - TY - JOUR AU - Gupta, S. K. AU - Vlahakis, N. E. PY - 2010 DA - 2010// TI - Integrin alpha9beta1: unique signaling pathways reveal diverse biological roles JO - Cell Adhes Migr VL - 4 UR - https://doi.org/10.4161/cam.4.2.10900 DO - 10.4161/cam.4.2.10900 ID - Gupta2010 ER - TY - JOUR AU - Hoye, A. M. PY - 2012 DA - 2012// TI - The newcomer in the integrin family: integrin alpha9 in biology and cancer JO - Adv Biol Regul VL - 52 UR - https://doi.org/10.1016/j.jbior.2012.03.004 DO - 10.1016/j.jbior.2012.03.004 ID - Hoye2012 ER - TY - JOUR AU - Asano, T. PY - 2014 DA - 2014// TI - Alpha9beta1 integrin acts as a critical intrinsic regulator of human rheumatoid arthritis JO - Rheumatology (Oxford) VL - 53 UR - https://doi.org/10.1093/rheumatology/ket371 DO - 10.1093/rheumatology/ket371 ID - Asano2014 ER - TY - JOUR AU - Emori, T. PY - 2017 DA - 2017// TI - Constitutive activation of integrin alpha9 augments self-directed hyperplastic and proinflammatory properties of fibroblast-like synoviocytes of rheumatoid arthritis JO - J Immunol VL - 199 UR - https://doi.org/10.4049/jimmunol.1700941 DO - 10.4049/jimmunol.1700941 ID - Emori2017 ER - TY - JOUR AU - Kanayama, M. PY - 2011 DA - 2011// TI - α9β1 integrin-mediated signaling serves as an intrinsic regulator of pathogenic Th17 cell generation JO - J Immunol VL - 187 UR - https://doi.org/10.4049/jimmunol.1101524 DO - 10.4049/jimmunol.1101524 ID - Kanayama2011 ER - TY - JOUR AU - Yamamoto, N. PY - 2003 DA - 2003// TI - Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis JO - J Clin Invest VL - 112 UR - https://doi.org/10.1172/JCI17778 DO - 10.1172/JCI17778 ID - Yamamoto2003 ER - TY - JOUR AU - Uede, T. PY - 2011 DA - 2011// TI - Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases JO - Pathol Int VL - 61 UR - https://doi.org/10.1111/j.1440-1827.2011.02649.x DO - 10.1111/j.1440-1827.2011.02649.x ID - Uede2011 ER - TY - JOUR AU - Sugahara, S. AU - Hanaoka, K. AU - Yamamoto, N. PY - 2018 DA - 2018// TI - Integrin, alpha9 subunit blockade suppresses collagen-induced arthritis with minimal systemic immunomodulation JO - Eur J Pharmacol VL - 833 UR - https://doi.org/10.1016/j.ejphar.2018.06.021 DO - 10.1016/j.ejphar.2018.06.021 ID - Sugahara2018 ER - TY - STD TI - Huang J, et al. Multiple dose safety, tolerability, pharmacokinetics, and pharmacodynamics of ASP5094, an anti-alpha9 integrin monoclonal antibody, in patients with rheumatoid arthritis on methotrexate [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). ID - ref38 ER - TY - JOUR AU - Tanaka, Y. PY - 2016 DA - 2016// TI - Efficacy and safety of Baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study JO - J Rheumatol VL - 43 UR - https://doi.org/10.3899/jrheum.150613 DO - 10.3899/jrheum.150613 ID - Tanaka2016 ER - TY - JOUR AU - Yamamoto, K. PY - 2014 DA - 2014// TI - Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial JO - Mod Rheumatol VL - 24 UR - https://doi.org/10.3109/14397595.2013.864224 DO - 10.3109/14397595.2013.864224 ID - Yamamoto2014 ER - TY - JOUR AU - Tanaka, Y. PY - 2012 DA - 2012// TI - Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study JO - Ann Rheum Dis VL - 71 UR - https://doi.org/10.1136/ard.2011.200317 DO - 10.1136/ard.2011.200317 ID - Tanaka2012 ER - TY - JOUR AU - Kanayama, M. PY - 2009 DA - 2009// TI - Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis JO - J Immunol VL - 182 UR - https://doi.org/10.4049/jimmunol.0900725 DO - 10.4049/jimmunol.0900725 ID - Kanayama2009 ER - TY - JOUR AU - Ohshima, S. PY - 2002 DA - 2002// TI - Enhanced local production of osteopontin in rheumatoid joints JO - J Rheumatol VL - 29 ID - Ohshima2002 ER -